Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 1/20 | 0.51 |
| ▸ | MAOB | P27338 | 1/20 | 0.51 |
| ▸ | TACR2 | P21452 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | GSK3B | P49841 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | DRD1 | P21728 | 1/20 | 0.47 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.46 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | UBE2N | P61088 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.45 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 3/20 | 0.45 |
| ▸ | RAB9A | P51151 | 3/20 | 0.45 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.45 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7371323 | 0.94 | MAOA (0.51) | MAOAMAOBTACR2SMN1; SMN2ALDH1A1 | |
| SCHEMBL29446267 | 0.87 | TACR2 (0.62) | MAOAMAOBTACR2SMN1; SMN2ALDH1A1 | |
| SCHEMBL584489 | 0.87 | TACR2 (0.62) | MAOAMAOBTACR2SMN1; SMN2ALDH1A1 | |
| SCHEMBL8889714 | 0.86 | AKR1C3 (0.50) | SMN1; SMN2ALDH1A1LMNADRD1AKR1C3 | |
| SCHEMBL18002005 | 0.86 | TACR2 (0.68) | TACR2SMN1; SMN2ALDH1A1LMNAAKR1C3 | |
| SCHEMBL2460248 | 0.86 | TACR2 (0.53) | MAOAMAOBTACR2SMN1; SMN2ALDH1A1 | |
| SCHEMBL24707029 | 0.84 | NPC1 (0.55) | TACR2SMN1; SMN2ALDH1A1LMNADRD1 | |
| SCHEMBL18001824 | 0.84 | POLB (0.49) | MAOAMAOBSMN1; SMN2ALDH1A1POLB | |
| SCHEMBL3568939 | 0.83 | RAB9A (0.68) | SMN1; SMN2ALDH1A1LMNAKDM4EPOLB | |
| SCHEMBL3568942 | 0.83 | RAB9A (0.68) | SMN1; SMN2ALDH1A1LMNAKDM4EPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260108497-A1 | OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION | OTSUKA PHARMACEUTICALC., LTD. (JP) | 2026-04-23 | — | — | US | disclosed |
| US-20240148699-A1 | OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2024-05-09 | — | — | US | disclosed |
| EP-3777979-B1 | ANTI-INFLAMMATORY COMPOUND AND PREPARATION AND USE THEREOF | E NITIATE BIOPHARMACEUTICALS HANGZHOU CO LTD (CN) | 2024-01-17 | — | — | EP | disclosed |
| CN-110407741-B | Anti-inflammatory compound and preparation and application thereof | 启元生物(杭州)有限公司 | 2023-03-21 | — | — | CN | disclosed |
| US-11440886-B2 | Anti-inflammatory compound, and preparation and use thereof | E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd. (CN) | 2022-09-13 | — | — | US | disclosed |
| US-20220265613-A1 | OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2022-08-25 | — | — | US | disclosed |
| CN-113912593-A | Deuterated pyridone compound and application thereof | 启元生物(杭州)有限公司 | 2022-01-11 | — | — | CN | disclosed |
| CN-110294732-B | Pharmaceutical compound for treating liver diseases and application thereof | 江苏新元素医药科技有限公司 | 2021-10-26 | — | — | CN | disclosed |
| CN-113121417-A | Novel piperidine derivative and pharmaceutical application thereof | 苏州盛迪亚生物医药有限公司 | 2021-07-16 | — | — | CN | disclosed |
| EP-3777979-A1 | ANTI-INFLAMMATORY COMPOUND AND PREPARATION AND USE THEREOF | Vivavision Biotech, Inc. (CN) | 2021-02-17 | — | — | EP | disclosed |
| US-7425567-B2 | Piperidine derivative compounds and drugs containing the compounds as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-09-16 | — | — | US | disclosed |
| US-7425567-B2 | Piperidine derivative compounds and drugs containing the compounds as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-09-16 | — | — | US | disclosed |
| EP-1954684-A2 | OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION | Otsuka Pharmaceutical Co., Ltd. (JP) | 2008-08-13 | — | — | EP | disclosed |
| WO-2008035316-A2 | PHOSPHODIESTERASE INHIBITORS | RANBAXY LABORATORIES LIMITED (IN) | 2008-03-27 | — | — | WO | disclosed |
| EP-1869054-A2 | CONDENSED ISOXALINE DERIVATIVES AS INHIBITORS OF PHOSPHODIESTERASE TYPE-IV | Ranbaxy Laboratories Limited (IN) | 2007-12-26 | — | — | EP | disclosed |
| WO-2007058338-A9 | OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION | OTSUKA PHARMA CO LTD (JP) | 2007-11-01 | — | — | WO | disclosed |
| WO-2007058338-A2 | OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-05-24 | — | — | WO | disclosed |
| WO-2006085212-A2 | CONDENSED ISOXALINE DERIVATIVES AS INHIBITORS OF PHOSPHODIESTERASE TYPE-IV | RANBAXY LABORATORIES LIMITED (IN) | 2006-08-17 | — | — | WO | disclosed |
| US-20050080107-A1 | Piperidine derivative compounds and drugs containing the compounds as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-04-14 | — | — | US | disclosed |
| EP-1481969-A1 | PIPERIDINE DERIVATIVE COMPOUNDS AND DRUGS CONTAINING THE COMPOUNDS AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-12-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240148699-A1 | OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION | PDE3B, PDE4A, PDE3A | MAOA 34/4885MAOB 61/4885TACR2 1228/4885 |
| US-20260108497-A1 | OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION | PDE7B, PDE4B, PDE1B | MAOA 126/4885MAOB 61/4885TACR2 1026/4885 |
| US-20050080107-A1 | Piperidine derivative compounds and drugs containing the compounds as the active ingredient | PDCD4, PDE4B, IRAK4 | MAOA 1167/4885MAOB 1214/4885TACR2 3881/4885 |
| US-11440886-B2 | Anti-inflammatory compound, and preparation and use thereof | PDE4B, PDE4A, PDE7A | MAOA 958/4885MAOB 1655/4885TACR2 2267/4885 |
| US-20220265613-A1 | OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION | PDE3B, PDE4A, PDE3A | MAOA 40/4885MAOB 80/4885TACR2 1270/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.